Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 02 Jan 2018 According to an ASLAN Pharmaceuticals media release, results were presented at the ESMO Asia 2017.
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 09 Feb 2017 Primary endpoint (Percentage change from baseline tumor size at Week 12) has been met, according to an ASLAN Pharmaceuticals Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History